This Biotech Stock’s Volatility Is Producing Huge Potential Gains This Month!
Big pharma is making a push right now to expand margins and investing billions into innovation for new treatments and drug therapies. In fact, drug companies have created venture capital funds and incubators to invest in promising start-ups working on new drug technologies.
Recently One Biotech Company has brought on new team members that have all had direct experience with many of the “industry leading” companies within the biotech industry.over the last 6 trading sessions, investors have already seen the volatile marktet for this stock spike up aa run of over 40%. After a recent day of consolidation, Wednesday’s late afternoon trading could be a cue for another run in the making!
PTC Therapeutics, Inc. Sets the Price for Public Offering of the Common Stock
PTC Therapeutics, Inc. has fixed the price of each share at $27.04 for the public offering of 4 million shares of the common stock. The public issue of the shares will close on April 3, 2018. The underwriters also have an option to purchase additional 600,000 shares of the common stock in a thirty day window at the same price of $27.04 for each share.
BIOTECHSTOCKS.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $1,800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending April. 30, 2018 to publicly disseminate information about (GTBP). We own zero shares. Full Disclaimer Here